Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 8:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 223 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ablative radiation treatment Clear all
Completed Phase 2 Interventional Results available

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

NCT03304639
View directory record Official record
Conditions
Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Interventions
Pembrolizumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
254
States / cities
Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 172 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NCT05657873
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Interventions
L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy
Radiation · Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Active, not recruiting Not applicable Interventional

Stereotactic Ablative Radiation Therapy for Prostate Cancer

NCT05668351
View directory record Official record
Conditions
Prostate Cancer
Interventions
SUPR-SABR treatment
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Active, not recruiting Phase 2 Interventional

Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer

NCT03523312
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Hypofractionated ablative IMRT (HFA-IMRT), capecitabine
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

NCT06260033
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Phase 3 Interventional

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

NCT05946213
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
1,209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2041
U.S. locations
402
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 303 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Not applicable Interventional Results available

Laser Treatment for Vulvar Lichen Sclerosus

NCT04134494
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
Ablative Fractional 2940 nm Laser
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia

NCT03349892
View directory record Official record
Conditions
Refractory Ventricular Tachycardia
Interventions
Stereotactic Ablative Radiotherapy (SABR)
Radiation
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

NCT04786093
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Stereotactic radiation therapy, Durvalumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Active, not recruiting Not applicable Interventional

Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer

NCT05830838
View directory record Official record
Conditions
Malignant Prostate Neoplasm
Interventions
Computed Tomography, Image-Guided Adaptive Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Active, not recruiting Phase 1 Interventional

A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer

NCT04040569
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiomics on MRI
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Suspended Phase 2 Interventional

Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer

NCT03164460
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Proton Radiation, Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Phase 3 Interventional Results available

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

NCT02762266
View directory record Official record
Conditions
Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
Interventions
Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent, lipiodol
Radiation · Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Phase 2 Interventional

A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)

NCT05851924
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
NALIRIFOX, AD-XRT and Capecitabine
Drug · Combination Product
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Not applicable Interventional

UroLift System With SAbR for Prostate Cancer and BPH

NCT05311527
View directory record Official record
Conditions
Prostate Cancer
Interventions
Urolift, SABR
Device · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Phase 3 Interventional Results available

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

NCT01730937
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
Sorafenib, stereotactic body radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
41
States / cities
Berkeley, California • Los Angeles, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Active, not recruiting Phase 2 Interventional

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

NCT03902951
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation

NCT06149780
View directory record Official record
Conditions
Healthy
Interventions
Patients treated with laser
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 15, 2026, 8:13 AM EDT
Completed No phase listed Observational

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676
View directory record Official record
Conditions
Prostate Cancer
Interventions
Proton beam
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Hyaluronidase Via LADD Scleroderma-induced Microstomia

NCT05995626
View directory record Official record
Conditions
Microstomia, Scleroderma
Interventions
Hyaluronidase, CO2 laser
Drug · Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Not applicable Interventional

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

NCT06101277
View directory record Official record
Conditions
Small Bowel Cancer, Colorectal Cancer, Appendiceal Cancer, Biliary Cancer, Gall Bladder Cancer, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Oligoprogressive
Interventions
Ablative local therapy
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2039
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

NCT03618134
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 15, 2026, 8:13 AM EDT
Terminated Phase 1Phase 2 Interventional

Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies

NCT04785287
View directory record Official record
Conditions
Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm, Malignant Adrenal Gland Neoplasm, Metastatic Liver Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Liver Cancer, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Liver Cancer, Stage IV Lung Cancer AJCC v8, Stage IVA Liver Cancer, Stage IVA Lung Cancer AJCC v8, Stage IVB Liver Cancer, Stage IVB Lung Cancer AJCC v8
Interventions
Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy
Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 15, 2026, 8:13 AM EDT
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 8:13 AM EDT